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estimate the burden of illness in PAH patients. Methods: Data came from a large 
commercial claims database. PAH patients were identified based on having > 2 medi-
cal claims for primary pulmonary hypertension (ICD-9 code:416.0), and either one 
claim for right heart catheterization or one claim of echocardiogram and diagnosed 
by a pulmonologist/cardiologist within 12 months of the medical claim. The first 
medical claim during this period served as in the index date with 12 months prior 
to this event as baseline and 12 months post as follow-up period. Demographic 
variables were extracted at a patient level from administrative files and economic 
variables, which included health care utilization and costs for outpatient, inpatient, 
emergency and pharmacy services came from the respective medical and pharmacy 
claim files and summarized at a per-patient-per-month (PPPM). Five controls were 
randomly picked and matched to each PAH patient on demographic characteristics. 
Incremental burden of PAH was estimated using non-parametric statistical tests 
between controls and PAH group. All costs were adjusted to 2012 base year using 
consumer price index. Results: A total of 2,245 PAH patients were identified and 
matched to 11,225 controls. PAH group had significantly higher (p< 0.001) PPPM 
health care utilization compared to the matched control across all drivers: outpa-
tient (2.6 vs. 1.5), inpatient (0.08 vs. 0.02), emergency room (0.1 vs. 0.04), and phar-
macy services (4.2 vs. 2.6). The increase in utilization translated in higher (p< 0.001) 
total PPPM incremental costs of $3,193 in the PAH group with inpatient ($1,665 
vs. $345) and pharmacy costs ($790 vs. $178) being as much as five times greater 
compared to controls. ConClusions: Health care resource use and costs for PAH 
patients is high from a managed care perspective.
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objeCtives: To describe the incidence and profile of patients hospitalised for acute 
heart failure (AHF); to assess the trajectories of patients before and after hospitaliza-
tion; and to estimate the cost of AHF inpatients stays. Methods: Patients with AHF 
were identified over a 5-year period (2006 - 2010) from the French PMSI (Programme 
de Médicalisation des Systèmes d’Information), a national disease-related group 
inpatient database. The PMSI database contains data related to all private and public 
hospital stays in France (about 20 millions/year). Heart failure was identified with 
the ICD-10, code I50. Results: The numbers of patients hospitalised at least once 
per year for AHF increased from 144,043 in 2006 to 158,623 in 2010. These num-
bers lead to incidence rates of 2.28‰ in 2006 and 2.45‰ in 2010. The proportion of 
patients aged ≥ 75 increased from 71.0% in 2006 to 74.3% in 2010. Half of patients 
were male. The mean number of comorbidities was 9.6 in 2010. The mean length of 
stay was 9.5 days and 12.6 days per year (2010), as mean re-hospitalization for AHF 
within the same year was 22%. The mean annual number of AHF hospitalisations 
per patient was 1.3. The mean cost for an AHF hospitalisation in the acute setting 
was 4,713€ in 2010. The mean annual cost for all hospitalisations occurring for a 
patient hospitalised at least once in a year (2010) for AHF was 6,253€ . Mean costs 
per hospital stay was higher if the patient died during hospitalisation (5,722€ vs. 
4,627€ , p< 0.001). Extrapolation to the whole country leads to a yearly cost of nearly 
a billion of euros (991 millions). ConClusions: Incidence of AHF hospitalisation 
increased in the recent years. This analysis highlighted the high economic hospital 
burden of AHF in France.
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objeCtives: Stroke has catastrophic consequences resulting in death or disability 
in 80% of patients and representing a substantial burden on the health care system, 
as well as on patients, family, and society. Stroke is considered as the 2ndcause of 
burden of disease in Europe and ischemic stroke (IS) represents a high percent-
age of total strokes. The objective of the present study was to analyze the first 
year post-stroke burden of IS in Spain. Methods: We performed an observational, 
multicenter, naturalistic and prospective study that included 16 hospitals (stroke 
units of National Health System hospitals) of 16 Spain regions. We took into con-
sideration consumption of health care resources, social burden, productivity lost 
and health-related quality of live of patient and caregiver during the first year 
post-stroke. Results: A total of 321 stroke patients were recruited. Mean age 72 
years, 54.8% male. Basal NIH stroke scale was 9.11 and 28.9% presented moderate-
high disability. 291 (90.7%) patients presented IS. Overall 1-year cost per IS was 
27,596.53€ . Direct health care costs were 8,623.35€ (31.25%), direct intrahospital 
health care costs supposed 69% (5,926.21€ ) of these costs. Direct non-health care 
costs were 18,377.75€ (66.59%), of which 16,515.09€ (59.84%) were informal care 
costs. Productivity lost was 595.43€ (2.16%). ConClusions: IS were the majority 
of total strokes in the study and represent a high burden on health care system and 
society, mainly due to hospitalization and informal care costs. Intrahospital costs 
were double than the published DRGs in Spain. Other diseases like Alzheimer or 
dementia represent a lower burden than stroke.
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objeCtives: To review published estimates of post-acute-care costs over one year 
in patients with acute coronary syndrome (ACS). Methods: Using the Medline and 
in EU5, a subject about which nothing has been published to date. Methods: A 
burden of illness model was constructed to examine the impact of RHT in EU5, 
specifically the incremental incidence, mortality and direct medical costs of CVD, 
which includes: coronary heart disease (CHD), congestive heart failure (CHF) and 
stroke. Framingham risk equations which included a coefficient for treatment resist-
ance and SCORE risk charts were used to estimate the risk of CVD for patients 
with and without RHT. Transition probability data were taken from the literature 
to estimate the risk of death from CVD events, subsequent CVD events and ESRD. 
Direct costs for these events and their long-term consequences were taken from 
the literature and from country-specific drug and acute inpatient costs. Results: 
The total direct medical cost of RHT in EU5 is estimated to be € 3.9 billion in 2013. 
This does not include the cost for drugs to treat RHT, or other costs such as lost 
productivity not directly borne by the health care system. RHT will contribute to 
188,000 cases of CHD, 57,400 strokes, 31,500 CHF and 1,400 ESRD and 30,000 deaths 
in 2013. ConClusions: The burden of RHT due to the increased incidence of CVD 
and ESRD is high. Reducing the incidence of CVD and ESRD through better blood 
pressure control should be a priority for health care decision makers.
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objeCtives: To analyze and estimate resource utilization and associated costs, 
one year following an acute episode of heart failure (HF) in Spain. Methods: 
Patient-flow data after index hospitalization for acute HF (AHF) were obtained 
from EAHFE database, an emergency (ER)-based registry containing records of all 
AHF patients treated in 29 Spanish hospitals (over 5,800 cases). Estimated medical 
resource utilization data during patients’ ER and other wards stay, hospitalization, 
and first-year follow-up was collected from medical specialists through question-
naire. AHF episodes and hospitalizations incident rates were estimated through 
literature review and disease statistics in official sources. Cost data was retrieved 
from Spanish Pharmacists official sources and a national health care costs database 
(Euros, 2013). To assess uncertainty, sensitivity analysis was carried out. Results: 
A total of 111,803 annual hospital admissions are estimated in Spain (2013). 92% 
of patients suffering an AHF episode are discharged alive and of these 90% survive 
the first month; 23% of these patients are discharged directly from ER, while the 
majority of those who are hospitalized, are admitted to Internal Medicine (53%) or 
Cardiology (17%) wards. On an average, patients are re-admitted 0.41 times within 1 
year. Total direct costs in the first year following an AHF episode averages € 6,822, of 
which 88% are incurred in hospital, with drugs and diagnostic tests accounting for 
less than 5% of all hospital costs. Follow-up costs, in average, split equally between 
drugs and outpatient visits/tests, but vary widely depending on local HF protocols. 
Extrapolation of results to the Spanish population suggests that the total burden of 
HF is more than € 542 million per year. ConClusions: Treating HF patients within 
Spain is resource intensive. Costs are primarily incurred in hospital and are mostly 
driven by the length of stay.
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objeCtives: Chronic thromboembolic hypertension (CTEPH) is associated with 
considerable morbidity and mortality. The objective of this study was to describe the 
burden of illness in patients with CTEPH. Methods: Data for this study came from 
a large commercial claims database. CTEPH patients were identified based on having 
> 2 medical claims for either primary pulmonary hypertension (ICD-9 code:416.0) or 
chronic pulmonary heart disease (ICD-9 code:416.8), history of pulmonary embolism 
in the past one year (ICD-9 code:415.1, V12.51, 38.7; CPT-4 codes:36010, 37620, 75825, 
75940; HCPCS codes:C1880) and either one claim for right heart catheterization 
or one claim of echocardiogram and diagnosed by a pulmonologist/cardiologist 
within 12 months of the medical claim. Demographic variables were extracted at 
a patient level from administrative files and economic variables, which included 
health care utilization and costs for outpatient, inpatient, emergency and pharmacy 
services came from the respective medical and pharmacy claim files and sum-
marized at a per-patient-per-month (PPPM). Five controls were randomly picked 
and matched to each CTEPH patient on demographic characteristics. Incremental 
burden of CTEPH was estimated using non-parametric statistical tests between 
controls and CTEPH group. All costs were adjusted to 2012 base year using consumer 
price index. Results: A total of 191 CTEPH patients were identified and matched 
to 955 controls. CTEPH group had significantly higher (p< 0.001) PPPM health care 
utilization compared to the matched control across all drivers: outpatient (3.1 vs. 
1.5), inpatient (0.13 vs. 0.02), emergency room (0.16 vs. 0.04), and pharmacy services 
(4.5 vs. 2.6). The increase in utilization translated in higher (p< 0.001) total PPPM 
incremental costs of $5,007 in the CTEPH group with inpatient ($3,909 vs. $332) and 
pharmacy costs ($607 vs. $180) being as much as twelve and three times greater 
compared to controls. ConClusions: Health care resource use and costs for CTEPH 
patients is high from a managed care perspective.
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objeCtives: Pulmonary arterial hypertension (PAH) is a progressive disease result-
ing in high health care resource use and costs. The objective of this study was to 
